Adenosine A2a receptor antagonists

A compound having the structural formula A

• 131
• or a pharmaceutically acceptable salt or solvate of said compound, wherein:
• R is selected from the group consisting of R1-furanyl-, R1-thienyl-, R1-pyridyl-, R1-oxazolyl-, R1-pyrrolyl- and R2-aryl-;
• X is —(CH2)n—;
• Y is a piperidinyl, pyrrolidinyl or azepanyl group with an aryl or heteroaryl moiety fused to two adjacent carbon atoms on Y, wherein X is attached to the N atom of the piperidinyl, pyrrolidinyl or azepanyl group;
• Q is 1-4 substituents, which can be the same or different, and are independently selected from the group consisting of hydrogen, cycloalkyl, cycloheteroalkyl, amino, aryl, aralkyl, heteroaryl, alkyl, CF3, halogen, NO2, alkoxy, alkoxyalkoxy, cycloalkylalkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamino, alkylaminosulfonyl, dialkylaminosulfonyl, —NH2SO2—, and hydroxy;
• n is 1 to 4;
• R1 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, CF3, halogen and NO2;
• and
• R2 is 1-3 substituents, which may be the same or different, and are independently selected from the group consisting of hydrogen, alkyl, —CF3, halogen, NO2, alkoxy, acyloxy, alkylamino, acylamino, alkylsulfonamido, alkylaminosulfonyl, dialkylaminosulfonyl, aminosulfonyl, and hydroxyl.